

Overview

While the cancer community hopes to CURE cancer, Calviri has developed the technologies to PREVENT cancer from occurring in the first place. Our discovery of a new class of cancer RNA-error-derived neoantigens enable us to produce early-stage diagnostics and off-the-shelf vaccines that are affordable. Our ultimate goal is a vaccine to prevent cancer worldwide.

- Series: Pre-Series-A, Bridge
- Industry: Cancer Vaccines and Diagnostics
- Market Size: >\$50B USA only
- People: 25
- Investment Opportunity: \$15M
- Use of Funds: Expand management team.
Commercialize dog diagnostic and preventative vaccine.

Executive Management



Stephen Albert Johnston,
Founder, CEO
Serial inventor: gene gun, nucleic acid vaccination, organelle transformation, >60 patents, National Academy of Inventors.



Jeffery Le Benger,
Chairman Board of Directors
Founder, former CEO of Summit Health, Chairman of the Board Summit Health

Current Status

Calviri has accomplished what everyone said could not be done: developed an effective preventative vaccine that reduces cancer incidence and deaths. We are preparing to commercialize the dog version of an early-stage, multi-cancer diagnostic and both preventative and therapeutic vaccines. In parallel, we are initiating clinical trials for analogous human products.

Milestones

We are completing the largest (800 dogs, 5 years) clinical trial ever conducted, evaluating our preventative vaccine. There is a 50% reduction in tumor incidence in vaccinated dogs, demonstrating for the first time that a broadly preventative cancer vaccine can be made. An Intel-like manufacturing system for diagnostic peptide chips has been established. We have raised \$23M to date from Board members and associated investors.

Challenge

Cancer is the 2nd leading cause of death worldwide. Most (75%) of these cancer deaths are in the developing world. The cancer field is focused on treating late-stage tumors using expensive therapies. These efforts will not alter cancer's grim future.

Solution

Calviri has made discoveries that allow us to create off-the-shelf vaccines and tests to detect cancer early. We will commercialize stage 1 diagnostics companioned with therapeutic vaccines. These products will be followed by a vaccine to prevent cancers worldwide.

Timeline & Market

2H 2024 Commercialization of dog diagnostic tests

1H 2025 Commercialization of dog preventative and therapeutic vaccines

2H 2025 Initiation of clinical trials of diagnostics and vaccines for people

Vaccine and Diagnostic Markets	Potential
Companion Animals	\$10B/yr USA
Humans	>\$50B/yr USA

Revenue Model

The companion animal products will be manufactured and marketed within Calviri. Proceeds will be used to speed Calviri's development of the human diagnostic and vaccine products. Calviri will manufacture the chips for both dog and human tests. We will have net revenue by 2026.

Competitive Advantage

Calviri is the only company that can produce off-the-shelf therapeutic and preventative cancer vaccines that are also affordable enough to address a worldwide market. Calviri's diagnostic technology solves the early detection problem of companies using nucleic acid or protein-based detection. We are the exclusive manufacturers of the chips that make this possible.

Exit

Our products will dominate both the pet and human cancer fields, marketed by Calviri as either a publicly sold company or remain private. If private, investors will obtain returns through stock buybacks and dividends.